PPARγ agonists as new therapeutic agents for the treatment of Alzheimer's disease
- 30 June 2006
- journal article
- review article
- Published by Elsevier in Experimental Neurology
- Vol. 199 (2), 245-248
- https://doi.org/10.1016/j.expneurol.2006.04.006
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusionEuropean Journal of Pharmacology, 2006
- Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammationNeurobiology of Aging, 2005
- Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β PeptideJournal of Neuroscience, 2004
- NUCLEAR RECEPTORS IN MACROPHAGE BIOLOGY: At the Crossroads of Lipid Metabolism and InflammationAnnual Review of Cell and Developmental Biology, 2004
- Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's diseaseJournal of Neurochemistry, 2002
- Inflammation and Alzheimer's diseaseNeurobiology of Aging, 2000
- Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E GenotypeAnnals of the New York Academy of Sciences, 2000
- Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ AgonistsJournal of Neuroscience, 2000
- Insulin Metabolism in Alzheimer’s Disease Differs According to Apolipoprotein E Genotype and GenderNeuroendocrinology, 1999
- Glucocorticoids and insulin resistance: old hormones, new targetsClinical Science, 1999